Mumbai-based pharmaceutical MNC Lupin Limited has announced the addition of Jeffrey Kindler and Alfonso “Chito” Zulueta to its board as independent directors, marking a significant milestone in bolstering its leadership team.

Mr. Kindler, a seasoned healthcare executive, investor, and advisor, brings with him over four decades of extensive business acumen. With a distinguished career that includes leadership roles at Pfizer, McDonald's Corporation, and General Electric Company, Mr. Kindler has been a driving force behind the success of numerous global enterprises. Currently serving as the CEO of Centrexion Therapeutics and holding advisory positions at Blackstone and ARTIS Ventures, Mr. Kindler's expertise spans across various sectors. His academic credentials boast a Bachelor of Arts degree from Tufts University and a Juris Doctor degree from Harvard Law School.

Mr. Zulueta, on the other hand, boasts a rich professional background spanning over three decades with Eli Lilly and Company. His tenure at Eli Lilly saw him ascend through various leadership roles, culminating in his appointment as President of International, overseeing operations across geographies. With a distinguished track record of contributions to the pharmaceutical industry, Mr. Zulueta currently serves as Non-Executive Chairman of Interpharma Investments Limited and heads CZ Ventures, a company focused on start-up investments. He holds an economics degree from De La Salle University and an MBA in marketing and finance from the University of Virginia.

In response to their appointments, Vinita Gupta, Lupin's CEO, expressed her delight, stating, "We are delighted to welcome Jeff and Chito to our board. Their extensive experience in building healthcare institutions, strategic perspectives of our industry, and deep understanding of the evolving global pharmaceutical landscape will enable us to advance our growth plans in the years to come."

The addition of Mr. Kindler and Mr. Zulueta to Lupin's Board underscores the company's commitment to fostering a diverse and seasoned leadership team capable of navigating the dynamic pharmaceutical landscape. With its wealth of experience and strategic insights, Lupin aims to further strengthen its position as a leading player in the global pharmaceutical arena.